Denali Therapeutics Inc. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
Denali Therapeutics Inc. (DNLI) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2025-02-27
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2022-12-31 was $23.00K.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2022-09-30 was $3.38M.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $0.00.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $3.40M, a 84850.00% increase from fiscal 2021.
- Denali Therapeutics Inc. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2021 was $4.00K, a 95.92% decline from fiscal 2020.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.40M derived: sum of 2 quarters · filed 2025-02-27 | $3.40M derived: sum of 3 quarters · filed 2025-02-27 | $3.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.38M 10-Q · filed 2023-11-07 | $3.38M derived: sum of 2 quarters · filed 2023-11-07 | $3.38M 10-Q · filed 2023-11-07 | $3.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $3.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $3.00K derived: sum of 3 quarters · filed 2024-02-28 | $4.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $3.00K derived: sum of 2 quarters · filed 2022-11-03 | $4.00K 10-Q · filed 2022-11-03 | $9.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-08 | $4.00K 10-Q · filed 2022-08-08 | $9.00K derived: sum of 3 quarters · filed 2023-02-27 | $14.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-05 | $6.00K derived: sum of 2 quarters · filed 2023-02-27 | $11.00K derived: sum of 3 quarters · filed 2023-02-27 | $47.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $10.00K derived: sum of 2 quarters · filed 2023-02-27 | $46.00K derived: sum of 3 quarters · filed 2023-02-27 | $98.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $5.00K 10-Q · filed 2021-11-04 | $41.00K derived: sum of 2 quarters · filed 2021-11-04 | $93.00K 10-Q · filed 2021-11-04 | $162.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $36.00K 10-Q · filed 2021-08-04 | $88.00K 10-Q · filed 2021-08-04 | $157.00K derived: sum of 3 quarters · filed 2022-02-28 | $253.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $52.00K 10-Q · filed 2021-05-05 | $121.00K derived: sum of 2 quarters · filed 2022-02-28 | $217.00K derived: sum of 3 quarters · filed 2022-02-28 | $316.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $165.00K derived: sum of 2 quarters · filed 2022-02-28 | $264.00K derived: sum of 3 quarters · filed 2022-02-28 | $358.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $96.00K 10-Q · filed 2020-11-05 | $195.00K derived: sum of 2 quarters · filed 2020-11-05 | $289.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $99.00K 10-Q · filed 2020-08-07 | $193.00K 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $94.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $60.00K 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |